Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$244.48
-$0.55(-0.40%)
At close: 4:00 PM EST
$244.48
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$160.86 - $250.74
Previous CloseN/A
Volume129.18K
Average Volume (3M)728.03K
Market Cap
$13.51B
Enterprise Value$12.20B
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)22.7
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume556,741
30 Day Avg. Volume728,030
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue14.06
Enterprise Value/Gross Profit15.95
Enterprise Value/Ebitda-1.76K
Forecast
1Y Price Target
$302.86Price Target Upside23.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)13.39
Revenue Forecast (FY)$1.34B
Bulls Say, Bears Say
Bulls Say
Strong Commercial Traction For YORVIPATH And SKYTROFADurable revenue base: rapid patient uptake and broadening prescriber base indicate sustainable product demand and expand recurring sales potential. Higher prescription volumes and expanding HCP coverage improve reimbursement leverage and scale benefits, supporting multi‑quarter growth in core endocrinology franchises.
High Gross Margins With Improving Cash GenerationVery high unit economics and positive operating/free cash flow signal durable profitability potential as revenue scales. Strong gross margin provides margin expansion runway; improving cash generation enhances self‑funding ability for commercialization and R&D without constant external financing over coming quarters.
Pipeline Depth Plus Regulatory Wins (YUVIWEL Approval, COACH Combo Data)Multiple late‑stage assets and positive combo data materially widen future indication and label expansion opportunities. FDA approval and orphan exclusivity provide protected commercial windows, while robust combination efficacy supports long‑term market differentiation in growth disorders and a higher probability of sustained revenue streams.
Bears Say
Elevated Leverage And Historic Negative EquityBalance‑sheet leverage constrains financial flexibility if operating performance weakens. High debt relative to equity increases refinancing and interest risks, and prior negative equity signals accumulated losses; sustained operating setbacks could force dilutive funding or curtailed investment over the next several quarters.
Earnings Quality Reliant On Non‑operating ItemsProfitability appears driven by one‑off accounting adjustments rather than recurring operations. If underlying EBIT/EBITDA remains negative, reported GAAP gains may not translate to durable cash flow, complicating forecasting and weakening confidence in sustainable earnings over the medium term.
Regulatory/legal And Supply Uncertainties For YUVIWELCommercial upside from a new approval is tempered by legal and manufacturing risk that can delay scale, constrain revenue cadence, or increase costs. Persistent capacity or import challenges could slow patient starts and reimbursement uptake, reducing visibility on sustainable sales growth over several quarters.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $160.86 and its highest was $250.74 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $13.51B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on May 07, 2026. The company reported $11.356 earnings per share for the quarter, beating the consensus estimate of $0.189 by $11.167.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is 1.83.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 62,376,846 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of $11.356 in its last earnings report, beating expectations of $0.189. Following the earnings report the stock price went up 4.341%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$302.86 (23.88% Upside)
$302.86 (23.88% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 302.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.37%
12-Months-Change
Fundamentals
Return on Equity
-5641.90%
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$302.86
▲(23.88% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
<0.01% Insiders
11.59% Mutual Funds
― Other Institutional Investors
86.12% Public Companies and
Individual Investors